Cancer-associated fibroblasts (CAFs) regulate tumour growth, metastasis and response to treatment. Recent studies indicate the existence of functionally distinct CAF subsets. Suggested mechanisms whereby CAFs can impact on treatment response include paracrine signalling affecting cancer cell drug sensitivity and effects on tumour drug uptake. PDGFRb is an important regulator of fibroblasts. Experimental studies have linked PDGFRb-positive fibroblasts to metastasis and also to reduced tumour drug uptake. This study has investigated the potential role of PDGFRb-positive fibroblasts in response to adjuvant tamoxifen treatment of breast cancer. Analyses of two breast cancer collections from randomised studies analysing adjuvant tamoxifen treatment in early breast cancer demonstrated significant benefit of tamoxifen in the group with low stromal PDGFRb, which was not observed in the group with high stromal PDGFRb. In general terms these findings provide novel evidence, derived from analyses of randomised clinical studies, of response-predictive capacity of a marker-defined subset of CAFs and, more specifically, identify stromal PDGFRb as a marker related to tamoxifen benefit in early breast cancer.
Introduction
Cancer growth, metastasis and response to treatment are influenced by cells of the tumour microenvironment, including cancer-associated fibroblasts (CAFs) [1] . CAFs can modulate drug response by different mechanisms including effects on tumour physiology which regulate tumour drug uptake or paracrine signalling altering cancer cell drug sensitivity [2] [3] [4] . CAF-derived markers, such as caveolin, stromal phospho-Erk (pErk), and stroma-derived gene signatures have been linked to sensitivity to chemotherapy and endocrine treatment [5] [6] [7] .
The PDGF family of growth factors, acting through PDGFRa and PDGFRb tyrosine kinase receptors, act as important regulators of CAFs [8, 9] . Previous studies have demonstrated that high stromal PDGFRb is linked to shorter survival in population-based breast and prostate tumour collections [10, 11] . Potential impact of PDGFRb-positive fibroblasts on drug sensitivity is suggested by mechanistic studies, which have demonstrated that PDGFR-signalling in fibroblasts can regulate treatment efficacy by controlling tumour drug uptake in a manner involving regulation of tumour interstitial fluid pressure [12, 13] .
Tamoxifen treatment represents a major component of clinical management of early breast cancer. Improved methods for identification of responsive patients remain a critical issue. Experimental and correlative studies have suggested a role for CAF-derived markers as biomarkers for tamoxifen benefit [14] [15] [16] .
This study extends these earlier findings by analyses of the potential of stromal PDGFRb as a tamoxifensensitivity biomarker through analyses of two randomised study-derived breast cancer collections.
Material and methods

Cohort 1
Premenopausal patients with stage II (pT1pN1, pT2pN0, pT2pN1) primary breast cancer (n 5 564) were randomised to 2 years of tamoxifen or no adjuvant treatment, in the SBII:2 multicentre trial [17] . Radiotherapy was delivered after breast conserving therapy and in patients with axillary lymph node metastases; chemotherapy and ovarian suppression was administered to <2% (nine patients). Median follow-up time was 13.6 years for patients without any event. Formalin fixed paraffin embedded blocks were retrieved from 500/564 patients and a tissue micro array (TMA) with two individual cores was constructed [17] . Assessment of ER, PR and HER2 were performed according to clinical protocols [18] .
For ER-and PR-status the clinically used cut-point of more than 10% was used.
Cohort 2
The Stockholm tamoxifen trial included a cohort of 1780 postmenopausal breast cancer patients with node negative disease and a tumour size not exceeding 30 mm, randomised to 2 years of tamoxifen or no adjuvant treatment, irrespective of hormone receptor status. Radiotherapy was administered to patients receiving breast-conserving therapy. No adjuvant chemotherapy was given in this group of patients. The trial has previously been described in more detail [19] . TMAs with three individual cores were constructed from formalin fixed paraffin embedded tumours from 912 patients. The assessments of ER, PR and HER2 with immunohistochemistry have been previously described [20] .
Immunohistochemistry
PDGFRb IHC for the pre-menopausal TMA series was performed as described earlier [21] . The post-menopausal TMA series was immunohistochemically stained for PDGFRb using the anti-PDGFRb antibody (#3169, 1:100 dilution, Cell Signaling Technology, USA) diluted in antibody diluent (Roche) in the Ventana system (Roche) with the Omnimap kit (5266548001, Roche). The secondary anti-rabbit antibody was used according to manufacturer's instructions (5269679001, Roche). For antigen retrieval high pH buffer was used (T6455, Sigma Aldrich). After 
Statistical analyses
The association of PDGFRb with other clinicopathological factors was evaluated using the v 2 -test. Time for follow-up was defined as the time from randomisation until the first event, loco-regional recurrence, distant recurrence, or death due to breast cancer. Survival curves and probabilities of recurrence-free survival (RFS) were estimated using the Kaplan-Meier method. Hazard ratios (HR) were calculated using Cox hazard regression analysis.
Results
Associations between stromal PDGFRb expression and clinico-pathological characteristics of early breast cancer TMAs from tumours of two different randomised studies on tamoxifen benefit in pre-and postmenopausal women [18, 19] , was subjected to PDGFRb IHC analyses and scored as previously described (Figure 1 ) [10, 11] .
High stromal PDGFRb expression was more common in the pre-menopausal group. In this group, 65% of cases displayed high stromal PDGFRb expression, whereas 42% of the post-menopausal cases displayed high levels of stromal PDGFRb expression (Table 1) .
In the post-menopausal cohort a significant association (p 5 0.023) was detected between high PDGFRb expression and small tumour size (Table  1) . No significant association between stromal PDGFRb expression and clinico-pathological features were detected in the pre-menopausal group.
Impact of stromal PDGFRb expression on RFS in tamoxifen-treated ER1 breast cancer
A set of analyses, restricted to ER1 cases, were performed which compared treatment effects in pre-and postmenopausal subsets defined by stromal PDGFRb status.
As shown in Figure 2A , a significant benefit of tamoxifen treatment (p 5 0.026), measured by Kaplan-Meier analyses of RFS, was detected in the low/moderate PDGFRb-expressing pre-menopausal group. Strikingly, this significant treatment benefit was not seen in the high PDGFRb expressing group. This differential effect of tamoxifen in the two markerdefined patient sub-groups was also seen in Cox regression analyses where treatment was associated with a significant HR in the low/moderate PDGFRbexpressing pre-menopausal group (HR 5 0.40 (95% CI 0.18-0.90)), but not in the high PDGFRb expressing group (HR 5 0.84 (95% CI 0.49-1.42)). Initial analyses of the complete post-menopausal cohort yielded results with a trend of reduced tamoxifen benefit in the subset with high stromal PDGFRb expression (data not shown). Based on findings from earlier meta-analyses that tamoxifen benefit is most prominent in cases with high ER expression novel analyses were performed on the subset of the postmenopausal cohort with more than 75% ER-positive cells (290 cases out of 393). Interestingly, analyses of this sub-group yielded results similar to those seen in the pre-menopausal cohort with significant tamoxifenbenefit, determined both by Kaplan-Meier analyses and Cox hazard regression analyses, detected in the PDGFRb low/moderate group (HR 5 0.41 (95% CI 0.23-0.73)), but not in the PDGFRb high group (HR 5 0.67 (95% CI 0.31-1.42)) ( Figure 2B ).
Together these analyses thus indicate that high stromal PDGFRb is a marker for reduced benefit of tamoxifen.
Discussion
In contrast to the majority of studies analysing factors associated with benefit of tamoxifen this study describes previously un-recognised associations between a tumour stroma marker and tamoxifen benefit.
Support for the notion that stromal fibroblasts can impact on efficacy of drugs targeting malignant cells, have been presented from analyses of series of cases not derived from randomised studies [6, 7] . The earlier analyses of the pre-menopausal cohort of the present study which identified pERK as a marker associated with tamoxifen efficacy, is to our knowledge the only other study which have demonstrated associations between a fibroblast-marker and treatment efficacy based on analyses of randomised studies [5] . The present findings thus represent a The present study identifies associations between stromal PDGFRb and tamoxifen benefit. Earlier studies have shown that stromal PDGFRb status is largely independent from stroma abundance in general or stromal a-smooth muscle actin-positivity [10, 22] . These findings therefore suggest that the detected association is not related to stroma abundance but rather reflects more specific biology of PDGFRb-positive stromal cells.
This study does not address if the detected association between stromal PDGFRb and tamoxifen benefit reflects a direct involvement of PDGFRb signalling in tamoxifen effects, or rather is related to other signalling effects of PDGFRb-positive stromal cells. Concerning the former, findings from model studies have demonstrated effects of stromal PDGFRb on tumour drug uptake [13, 23, 24] . Paracrine signalling from fibroblasts have also been shown to directly affect drug efficacy [2, 25, 26] . Previous experiments have indeed demonstrated tamoxifen-protective effects by cocultured fibroblasts in tissue culture models [14] [15] [16] . According to preliminary studies this effect is not related to PDGFRb status of fibroblasts, since also fibroblast with down-regulation of PDGFRb displayed a protective effect (data not shown). The clinical associations therefore appear more likely to be related to PDGFRb-controlled drug exposure. Future studies could explore this possibility be measuring tamoxifen uptake, or ER activity, in tumour samples with known stromal PDGFRb status from tamoxifen treated cases.
Both cohorts represent randomised clinical trials with long time of follow-up, of importance as patients with ER-positive breast cancer frequently experience late relapses. With few exceptions the patients received no other systemic treatment than tamoxifen. A limitation is that the study is retrospective and at the time when the trials were implemented less women than today had breast conserving surgery. Type of surgery had however no influence on the results (data not shown).
Based on the results from the present study it seems highly appropriate to integrate fibroblastrelated markers, in general, and PDGFRb, specifically, in future prospective efforts to identify tamoxifen-benefit biomarkers.
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